Parkinson's disease

While Hunter syndrome represents a relatively small commercial opportunity, Denali has a clinical and preclinical pipeline of assets leveraging this technology, including for Sanfilippo syndrome—where the FDA has granted an accelerated approval path—Fabry disease, Parkinson’s disease, and Alzheimer’s disease, among others.

In Parkinson's disease, this protein sticks together into toxic clumps that cause nerve cell death and leads to patients suffering from symptoms such as tremors, difficulties moving and muscle stiffness.

Researchers at the University of Bath, in collaboration with the Universities of Oxford and Bristol, have developed a molecule that prevents the clumping and build-up of a protein linked to Parkinson's disease and related dementias.

After Leo's death from Parkinson's disease, she faced life alone.

Bill Plaschke has now written two marvelous columns related to Parkinson’s Disease and his experience with it.